|
|
May 20, 2007: India’s top drug maker
Ranbaxy Laboratories’s US subsidiary is likely to
receive approval for the generic version of the
commonly used drug to treat allergic rhinitis.
Ranbaxy said in a press statement that the federal
drug regulator United States Food and Drug
Administration (USFDA) has given conditional okay
for manufacturing and marketing Fexofenadine
Hydrochloride tablets.
Fexofenadine Hydrochloride is used for relieving
symptoms of seasonal rhinitis like sneezing,
rhinorrhea, itchy nose, throat, palate and eyes.
Total annual market sales for Fexofenadine
Hydrochloride Tablets were pegged at 931 million
dollars and the nod will further expand the
company's product portfolio of generic
alternatives, Ranbaxy said.
"This product represents a future opportunity for
Ranbaxy and will be launched following final
approval from the FDA," RPI Vice President (Sales
and Marketing) Jim Meehan said in a communique to
the BSE.
The approval will allow Florida-based RPI, engaged
in selling and distribution of generic as well as
branded prescription products in US, to make and
market the tablets in three dosages, 30 mg, 60 mg,
and 180 mg.
BY OUR PHARMA CORRESPONDENT
|
